Table 3.
Intravenous nanoparticle therapies and diagnostics which are not clinically approved and are currently undergoing clinical trials (not yet recruiting, recruiting, enrolling by invitation, or active)
| Name (company) | Particle type/drug | Investigated application/indication | Current ClinicalTrials.gov identifiers (phase) |
|---|---|---|---|
| Liposomes (cancer) | |||
| MM‐310 (Merrimack Pharmaceuticals) |
Nanoliposomal encapsulated docetaxel and functionalized with antibodies targeted to the EphA2 receptor | Solid tumors | NCT03076372 (Ph I): Recruiting |
| EGFR(V)‐EDV‐Dox (EnGeneIC) |
Bacterially derived minicell encapsulating doxorubicin | Recurrent glioblastoma | NCT02766699 (Ph I): Recruiting |
| Alprostadil liposome (CSPC ZhongQi Pharmaceutical Technology) |
Alprostadil liposome | Safety and tolerability | NCT03669562 (Ph I): Recruiting |
| Liposomal Annamycin (Moleculin Biotech) |
Liposomal Annamycin | Acute myeloid leukemia |
NCT03388749 (Ph II): Recruiting NCT03315039 (Ph II): Recruiting |
| FF‐10831 (Fujifilm Pharmaceuticals) |
Liposomal Gemcitabine | Advanced solid tumors | NCT03440450 (Ph I): Recruiting |
| Anti‐EGFR‐IL‐dox (Swiss Group for Clinical Cancer Research; University Hospital, Basel, Switzerland) |
Doxorubicin‐loaded anti‐EGFR immunoliposomes | Advanced triple negative EGFR positive breast cancer High grade gliomas |
NCT02833766 (Ph II): Recruiting NCT03603379 (Ph I): Recruiting |
| TLD‐1/Talidox (InnoMedica) |
A new formulation of liposomal doxorubicin | Advanced solid tumors | NCT03387917 (Ph I): Recruiting |
| NC‐6300 (NanoCarrier) |
Micelle encapsulated epirubicin | Advanced solid tumors or soft tissue sarcoma | NCT03168061 (Ph II): Recruiting |
| Liposomes (gene therapy: Cancer) | |||
| MRT5201 (Translate Bio) |
mRNA encapsulated in PEGylated liposomes | Ornithine transcarbamylase deficiency | NCT03767270 (Ph I): Not yet recruiting |
| Lipo‐MERIT (Biontech RNA Pharmaceuticals) |
Four naked ribonucleic acid (RNA)‐drug products formulated with liposomes | Cancer vaccine for advanced melanoma | NCT02410733 (Ph I): Recruiting |
| Liposomes (immunotherapy: Cancer) | |||
| IVAC_W_bre1_uID | Patient‐specific liposome (specificity for antigen‐expression on a patient's tumor) complexed RNA | Triple negative breast cancer | NCT02316457 (Ph I): Recruiting |
| Liposomes (gene therapy: Vaccine) | |||
| mRNA‐1944 (Moderna) |
Two mRNAs that encode heavy and light chains of anti‐Chikungunya antibody formulated in Moderna's proprietary lipid nanoparticle technology | Safety, tolerability, pharmacokinetics and pharmacodynamics towards the prevention of Chikungunya virus infection | NCT03829384 (Ph I): Recruiting |
| Micelles (cancer) | |||
| MTL‐CEBPA (Mina alpha) |
Double stranded RNA formulated into SMARTICLES amphoteric liposomes | Advanced liver cancer | NCT02716012 (Ph I): Recruiting |
| Imx‐110 (Immix Biopharma Australia) |
Micelle encapsulating a Stat3/NF‐kB/poly‐tyrosine kinase inhibitor and low‐dose doxorubicin | Advanced solid tumors | NCT03382340 (Ph I): Recruiting |
| IT‐141 (Intezyne Technologies) |
Micelle formulation of SN‐38 | Advanced cancer | NCT03096340 (Ph I): Recruiting |
| Inorganic nanoparticles (cancer) | |||
| NU‐0129 (Northwestern) |
Spherical nucleic acid platform consisting of nucleic acids arranged on the surface of a spherical gold nanoparticle | Glioblastoma | NCT03020017 (Ph I): Active, not recruiting |
| Nanoparticles for imaging applications | |||
| AGuIX (National Cancer Institute, France) |
Polysiloxane Gd‐Chelates‐based nanoparticles | Advanced cervical cancer | NCT03308604 (Ph I): Recruiting |
| ONM‐100 (OncoNano Medicine) |
Micelle covalently conjugated to indocyanine green | Intraoperative detection of cancer | NCT03735680 (Ph II): Not yet recruiting |
Note: These trials and nanoparticles have appeared on the ClinicalTrial.gov database since 2016. Trials are grouped by particle type and indication.